Author details

Full Name

Weiwei Shi

Affiliation

ORCID

Career Start Year

2008

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
35851588	Genomic profiling and the impact of MUC19 mutation in hepatoid adenocarcinoma of the stomach.	Cancer Communications	2022
34026777	Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms.	Frontiers in Medicine	2021
32832493	Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.		2020
32256810	Comprehensive genomic profile of cholangiocarcinomas in China.	Oncology Letters	2020
32236597	Characterization of genomic alterations and the significance of PI3K/mTOR pathway mutations and tumor mutational burden in nonâ¿¿small cell lung cancer.	Oncology Reports	2020
32533190	Characteristics of genomic alterations in Chinese cholangiocarcinoma patients.	Japanese Journal of Clinical Oncology	2020
33288739	Identification of "regulation of RhoA activity panel" as a prognostic and predictive biomarker for gastric cancer.	Aging	2020
31409745	An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.	Oncologist	2019
31692284	Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy.	Cancer Medicine	2019
31612912	Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.	Japanese Journal of Clinical Oncology	2019
31700903	Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice.	Annals of Translational Medicine (discontinued)	2019
30624555	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.	Ann Oncol	2019
29701764	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.	Ann Oncol	2018
30404001	Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity.	Cell Rep	2018
30652574	TQuest, A Web-Based Platform to Enable Precision Medicine by Linking a Tumor's Genetic Defects to Therapeutic Options.	JCO clinical cancer informatics	2018
27959926	Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis.	PLoS Med	2016
26980737	Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools.	Oncotarget	2016
26420498	Characterization of DNA variants in the human kinome in breast cancer.	Sci Rep	2015
26136146	Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments.	PLoS One	2015
26502353	Standardization efforts enabling next-generation sequencing and microarray based biomarkers for precision medicine.	Biomarkers in Medicine	2015
24602449	Global gene expression changes induced by prolonged cold ischemic stress and preservation method of breast cancer tissue.	Molecular Oncology	2014
25395317	Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets.	Breast Cancer Research and Treatment	2014
25294321	Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer.	BMC Genomics	2014
24619174	Combined analysis of gene expression, DNA copy number, and mutation profiling data to display biological process anomalies in individual breast cancers.	Breast Cancer Research and Treatment	2014
24286516	The influence of cathelicidin LL37 in human anti-neutrophils cytoplasmic antibody (ANCA)-associated vasculitis.		2013
22952733	Dynamic status of REST in the mouse ESC pluripotency network.	PLoS One	2012
22291085	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry.	J Clin Oncol	2012
21398405	Functional synergies yet distinct modulators affected by genetic alterations in common human cancers.	Cancer Res	2011
20064235	Effect of training-sample size and classification difficulty on the accuracy of genomic predictors.	Breast Cancer Res	2010
20676074	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.	Nat Biotechnol	2010
20676069	Functional analysis of multiple genomic signatures demonstrates that classification algorithms choose phenotype-related genes.	Pharmacogenomics J	2010
20676067	A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data.	Pharmacogenomics J	2010
20676066	Genomic indicators in the blood predict drug-induced liver injury.	Pharmacogenomics J	2010
20676064	Consistency of predictive signature genes and classifiers generated using different microarray platforms.	Pharmacogenomics J	2010
20158879	Bimodal gene expression patterns in breast cancer.	BMC Genomics	2010
20020920	Characteristics of genomic signatures derived using univariate methods and mechanistically anchored functional descriptors for predicting drug- and xenobiotic-induced nephrotoxicity.	Toxicology Mechanisms and Methods	2008
19014478	A comprehensive functional analysis of tissue specificity of human gene expression.	BMC Biology	2008